Celldex Therapeutics, Inc. (CLDX)

Market Cap	1.21B
Revenue (ttm)	7.02M
Net Income (ttm)	-157.86M
Shares Out	66.38M
EPS (ttm)	-2.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	457,852
Open	18.13
Previous Close	17.80
Day's Range	17.84 - 18.32
52-Week Range	14.40 - 47.00
Beta	1.59
Analysts	Buy
Price Target	54.29 (+196.83%)
Earnings Date	May 5, 2025

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, pr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 10, 2008
• Employees: 186
• Stock Exchange: NASDAQ
• Ticker Symbol: CLDX
• Website: https://www.celldex.com

Financial Performance

In 2024, Celldex Therapeutics's revenue was $7.02 million, an increase of 1.99% compared to the previous year's $6.88 million. Losses were -$157.86 million, 11.6% more than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is $54.29, which is an increase of 196.83% from the latest price.

Price Target

$54.29

(196.83% upside)

Analyst Consensus: Buy